Researchers from Canada presented the retrospective chart review of 2 siblings with ST3GAL3-related developmental and epileptic encephalopathy (DEE), a very rare condition that can evolve into Lennox-Gastaut syndrome. “Seizures . . . often occur in infancy and may present as epileptic spasms,” the researchers wrote in a report they published in the journal Epilepsia Open. Read…
A newly identified mice model could serve as an accurate simulation of Lennox-Gastaut syndrome (LGS), according to a study recently published in Molecular and Cellular Mechanisms of Epilepsy. “We find it particularly important to study mutants of genes encoding GABAAR subunits, since these tend to directly impair inhibitory neurotransmission, thus causing a perturbation in the…
In a new study published in Epilepsia, researchers found that highly purified cannabidiol (CBD) treatment in patients with Lennox–Gastaut syndrome (LGS) resulted in an increase in both drop and total seizure-free days, suggesting that seizure-free days could be a more meaningful indication of the actual everyday benefits of CBD treatment for patients with LGS. The post hoc…
Perampanel seems safe and efficient for the treatment of some patients with rare genetic epilepsies, including Lennox-Gastaut syndrome (LGS), according to a new study published in the journal Epilepsia. The treatment led to high seizure reduction, which was maintained, and higher efficacy in certain genetic variants, including SCN1A, suggesting a targeted effect related to glutamate transmission.…
Soticlestat is associated with sustained seizure reductions in patients with Lennox-Gastaut syndrome and Dravet syndrome, according to interim data from an ongoing phase 2 clinical trial presented at the American Academy of Neurology’s (AAN) 75th Annual Meeting between April 22 and 27 in Denver, Colorado. Safety findings from the interim analysis were consistent with previous…
Patients with Lennox–Gastaut syndrome receiving soticlestat as adjunctive therapy had reduced median frequency in specific types of seizures according to a post hoc analysis of results from a clinical trial called Elektra, which were presented at the American Academy of Neurology’s (AAN) 75th Annual Meeting held in Denver, Colorado, between April 22 and 27, 2023.…
A new study published in the Annals of Child Neurology has strongly recommended lamotrigine (LTG) as a complementary therapy for children with Lennox-Gastaut syndrome (LGS). The study found that 92.1% of the LGS patients received valproate (VPA) simultaneously, and 54.5% of them were reported to have a significant (>50%) reduction in seizure frequency, indicating the effectiveness of LTG as…
The use of perampanel (PER) as an adjuvant treatment appears to decrease seizure relapse in patients with Lennox–Gastaut syndrome (LGS), according to a recently published study in Epilepsy. LGS is characterized by a poor response toward pharmacologic therapeutic measures. Despite the widespread use of antiepileptic drugs such as valproic acid, there is still an urgent…
The use of pharmaceutical cannabidiol (CBD) in Lennox-Gastaut syndrome and Dravet syndrome is beneficial both in terms of seizure reduction and improvements in patients’ quality of life, according to a new Italian study published in the journal Expert Opinion on Pharmacotherapy. However, the authors warned that more research is necessary to confirm the effects of…
Please login or register first to view this content.
